Company intelligence / Profile preview

Andreas Kranzusch

Ownership: Private
Employees: ~10
Development stage: Other

Overview

Cefepime/enmetazobactam demonstrated superiority over standard-of-care in Phase 3 trials for complicated urinary tract infections. The combination has received FDA and EMA approval for cUTI and is marketed in Europe by Advanz Pharma and in the Gulf Cooperation Council countries/South Africa by Acino. Submissions are being prepared for further marketing approvals.

Therapeutic areas: Infectious Diseases
Modalities: Small moleculeBeta-lactam antibioticBeta-lactamase inhibitor
Industry: Biotech

Partnerships

Advanz PharmaAcinoShanghai Haini Pharmaceutical Co.

Beyond the preview

Go deeper on Andreas Kranzusch.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Andreas Kranzusch.

Explore the full profile